Genmab — Februar 2018
-
Det er da set værre. Lad os se hvordan USA kommer i gang i dag.
-
-
this Ofa study on CLL/SLL just completed; should we expect any data on that or is it completely out of the picture now?
https://clinicaltrials.gov/ct2/show/NCT01002755?term=daratumumab+OR+ofatumumab&lupd_s=02%2F01%2F2018&rank=7 -
Ser fornuftigt ud i dag. A/B forsætter det store nettokøb som vi nu har set i et stykke tid.
-
Celgene announces Positive Results from the Pivotal Phase III OPTIMISM study - evaluated the efficacy and safety of POMALYST/IMNOVID (pomalidomide) plus bortezomib and low-dose dexamethasone (PVd) versus bortezomib and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. It is the only phase III trial to investigate a triplet combination in patients who have all received prior lenalidomide (REVLIMID
), a population for which there is a growing unmet medical need
rigtig god dag til jer alle
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind